Effect of diabetes mellitus on the outcomes of total ankle arthroplasty: is controlled diabetes mellitus a risk factor?
Clinical outcomes
Complications
Diabetes mellitus
Total ankle arthroplasty
Journal
Journal of orthopaedic surgery and research
ISSN: 1749-799X
Titre abrégé: J Orthop Surg Res
Pays: England
ID NLM: 101265112
Informations de publication
Date de publication:
29 Aug 2023
29 Aug 2023
Historique:
received:
16
07
2023
accepted:
17
08
2023
medline:
31
8
2023
pubmed:
30
8
2023
entrez:
29
8
2023
Statut:
epublish
Résumé
It is still uncertain whether diabetes mellitus (DM) is a risk factor for poor outcomes and increased complications after total ankle arthroplasty (TAA). The objective of this study was to compare clinical outcomes and complication rates of TAA in patients with and without DM. This study enrolled patients with symptomatic end-stage ankle osteoarthritis with a minimum follow-up period of 24 months after TAA. A total of 252 patients (266 ankles) were classified into two groups according to the presence of DM: (1) DM group (59 patients, 67 ankles) and (2) non-DM group (193 patients, 199 ankles). We defined controlled diabetes as (1) HbA1c level < 7.0%, or (2) fasting glucose level < 130 mg/dL with HbA1c level ≥ 7.0% for hospitalization period. Clinical outcomes data (Ankle Osteoarthritis Scale, American Orthopedic Foot and Ankle Society ankle-hindfoot score, Short Form-36 Physical Component Summary score, and visual analog scale for pain) were compared preoperatively and at the final follow-up between the two groups. Complications following TAA were also compared between the two groups. All clinical variables had improved in both groups by the final follow-up (mean follow-up = 77.8 months). There was no significant difference in any clinical variable between the two groups at the final follow-up (P > 0.05). Of the 266 ankles, 73 ankles (19 in the DM group, 54 in the non-DM group) developed periprosthetic osteolysis. Although the DM group showed a higher prevalence of aseptic loosening or subsidence, the difference between the two groups was not statistically significant (P = 0.236). In the intermediate-term follow-up, TAA in patients with controlled DM showed clinical outcomes and complication rates comparable to patients without DM. Our results suggest that TAA can be done safely in diabetic patients if the DM is controlled in the perioperative period. Therapeutic Level III.
Sections du résumé
BACKGROUND
BACKGROUND
It is still uncertain whether diabetes mellitus (DM) is a risk factor for poor outcomes and increased complications after total ankle arthroplasty (TAA). The objective of this study was to compare clinical outcomes and complication rates of TAA in patients with and without DM.
METHODS
METHODS
This study enrolled patients with symptomatic end-stage ankle osteoarthritis with a minimum follow-up period of 24 months after TAA. A total of 252 patients (266 ankles) were classified into two groups according to the presence of DM: (1) DM group (59 patients, 67 ankles) and (2) non-DM group (193 patients, 199 ankles). We defined controlled diabetes as (1) HbA1c level < 7.0%, or (2) fasting glucose level < 130 mg/dL with HbA1c level ≥ 7.0% for hospitalization period. Clinical outcomes data (Ankle Osteoarthritis Scale, American Orthopedic Foot and Ankle Society ankle-hindfoot score, Short Form-36 Physical Component Summary score, and visual analog scale for pain) were compared preoperatively and at the final follow-up between the two groups. Complications following TAA were also compared between the two groups.
RESULTS
RESULTS
All clinical variables had improved in both groups by the final follow-up (mean follow-up = 77.8 months). There was no significant difference in any clinical variable between the two groups at the final follow-up (P > 0.05). Of the 266 ankles, 73 ankles (19 in the DM group, 54 in the non-DM group) developed periprosthetic osteolysis. Although the DM group showed a higher prevalence of aseptic loosening or subsidence, the difference between the two groups was not statistically significant (P = 0.236).
CONCLUSIONS
CONCLUSIONS
In the intermediate-term follow-up, TAA in patients with controlled DM showed clinical outcomes and complication rates comparable to patients without DM. Our results suggest that TAA can be done safely in diabetic patients if the DM is controlled in the perioperative period.
LEVEL OF EVIDENCE
METHODS
Therapeutic Level III.
Identifiants
pubmed: 37644589
doi: 10.1186/s13018-023-04110-y
pii: 10.1186/s13018-023-04110-y
pmc: PMC10463683
doi:
Substances chimiques
Glycated Hemoglobin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
636Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
J Bone Joint Surg Am. 2013 Mar 20;95(6):481-7
pubmed: 23446446
Diabetes Ther. 2019 Jun;10(3):853-863
pubmed: 31037553
Bone Joint J. 2019 Jan;101-B(1):47-54
pubmed: 30601052
Foot Ankle Int. 2020 Aug;41(8):937-944
pubmed: 32538146
Clin Podiatr Med Surg. 2013 Jan;30(1):1-20
pubmed: 23164436
Acta Orthop. 2018 Aug;89(4):399-405
pubmed: 29757058
Br Med Bull. 2009;89:111-51
pubmed: 19008282
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
J Bone Joint Surg Am. 2014 Mar 19;96(6):500-4
pubmed: 24647507
Foot Ankle Int. 2017 Apr;38(4):360-366
pubmed: 28367692
Foot Ankle Int. 1994 Jul;15(7):349-53
pubmed: 7951968
Arch Public Health. 2015 Sep 25;73:43
pubmed: 26413295
J Bone Joint Surg Am. 2019 Sep 4;101(17):1523-1529
pubmed: 31483394
J Bone Joint Surg Am. 2019 Dec 18;101(24):2203-2211
pubmed: 31596804
J Bone Joint Surg Am. 2022 May 18;104(10):881-888
pubmed: 35290251
J Orthop Surg Res. 2020 Jun 5;15(1):207
pubmed: 32503581
J Bone Joint Surg Am. 2006 Jun;88(6):1272-84
pubmed: 16757761
Bone Joint J. 2019 Jun;101-B(6):695-701
pubmed: 31154845
Clin Nutr. 2016 Apr;35(2):308-316
pubmed: 25840840
Foot Ankle Int. 1998 Jul;19(7):466-71
pubmed: 9694125
Br Med Bull. 2017 Dec 01;124(1):91-112
pubmed: 29186357
Foot Ankle Int. 2015 Oct;36(10):1144-9
pubmed: 25948694
Orthopedics. 2020 Nov 1;43(6):e515-e522
pubmed: 32882052
Foot Ankle Int. 2012 Jan;33(1):20-8
pubmed: 22381232
Clin Orthop Relat Res. 2015 May;473(5):1726-31
pubmed: 25404402
J Arthroplasty. 2013 Sep;28(8 Suppl):25-9
pubmed: 23910511
Biomark Insights. 2016 Jul 03;11:95-104
pubmed: 27398023
Clin Orthop Relat Res. 2010 Jan;468(1):199-208
pubmed: 19618248
Foot Ankle Int. 2012 Jan;33(1):57-63
pubmed: 22381237
J Bone Joint Surg Am. 2015 May 20;97(10):818-23
pubmed: 25995492
J Am Acad Orthop Surg. 2020 Aug 15;28(16):661-670
pubmed: 32769721
Bone Joint J. 2014 Dec;96-B(12):1674-80
pubmed: 25452372
J Bone Joint Surg Am. 2009 May;91(5):1042-9
pubmed: 19411451
Foot Ankle Int. 2015 Mar;36(3):258-67
pubmed: 25413307
Foot Ankle Spec. 2022 Jun;15(3):201-208
pubmed: 32830583
Foot Ankle Int. 2019 Jul;40(7):762-768
pubmed: 30971117